Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does FLUDARABINE Cause Second primary malignancy? 223 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 223 reports of Second primary malignancy have been filed in association with FLUDARABINE (Fludarabine Phosphate). This represents 0.9% of all adverse event reports for FLUDARABINE.

223
Reports of Second primary malignancy with FLUDARABINE
0.9%
of all FLUDARABINE reports
121
Deaths
10
Hospitalizations

How Dangerous Is Second primary malignancy From FLUDARABINE?

Of the 223 reports, 121 (54.3%) resulted in death, 10 (4.5%) required hospitalization, and 14 (6.3%) were considered life-threatening.

Is Second primary malignancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for FLUDARABINE. However, 223 reports have been filed with the FAERS database.

What Other Side Effects Does FLUDARABINE Cause?

Off label use (3,018) Febrile neutropenia (2,055) Drug ineffective (1,630) Pyrexia (1,606) Product use in unapproved indication (1,530) Cytokine release syndrome (1,458) Neutropenia (1,175) Cytomegalovirus infection (1,132) Mucosal inflammation (1,036) Sepsis (981)

What Other Drugs Cause Second primary malignancy?

CYCLOPHOSPHAMIDE (1,247) DOXORUBICIN (1,151) VINCRISTINE (908) IMATINIB (763) PALBOCICLIB (658) RITUXIMAB (646) RUXOLITINIB (611) ETOPOSIDE (573) PREDNISONE (517) OCTREOTIDE (496)

Which FLUDARABINE Alternatives Have Lower Second primary malignancy Risk?

FLUDARABINE vs FLUDEOXYGLUCOSE F-18 FLUDARABINE vs FLUDROCORTISONE FLUDARABINE vs FLUINDIONE FLUDARABINE vs FLUMAZENIL FLUDARABINE vs FLUMETHASONE

Related Pages

FLUDARABINE Full Profile All Second primary malignancy Reports All Drugs Causing Second primary malignancy FLUDARABINE Demographics